Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants

Int J Mol Sci. 2022 Jun 13;23(12):6587. doi: 10.3390/ijms23126587.

Abstract

Broadly effective and safe anti-coronavirus agent is existentially needed. Major protease (3CLpro) is a highly conserved enzyme of betacoronaviruses. The enzyme plays pivotal role in the virus replication cycle. Thus, it is a good target of a broadly effective anti-Betacoronavirus agent. In this study, human single-chain antibodies (HuscFvs) of the SARS-CoV-2 3CLpro were generated using phage display technology. The 3CLpro-bound phages were used to infect Escherichia coli host for the production the 3CLpro-bound HuscFvs. Computerized simulation was used to guide the selection of the phage infected-E. coli clones that produced HuscFvs with the 3CLpro inhibitory potential. HuscFvs of three phage infected-E. coli clones were predicted to form contact interface with residues for 3CLpro catalytic activity, substrate binding, and homodimerization. These HuscFvs were linked to a cell-penetrating peptide to make them cell-penetrable, i.e., became superantibodies. The superantibodies blocked the 3CLpro activity in vitro, were not toxic to human cells, traversed across membrane of 3CLpro-expressing cells to co-localize with the intracellular 3CLpro and most of all, they inhibited replication of authentic SARS-CoV-2 Wuhan wild type and α, β, δ, and Omicron variants that were tested. The superantibodies should be investigated further towards clinical application as a safe and broadly effective anti-Betacoronavirus agent.

Keywords: SARS-CoV-2; cell-penetrating antibody; human single-chain antibody variable fragments (HuscFvs); major protease (3CLpro); superantibody.

MeSH terms

  • COVID-19 Drug Treatment*
  • Coronavirus 3C Proteases
  • Escherichia coli
  • Humans
  • Protease Inhibitors / pharmacology
  • SARS-CoV-2*

Substances

  • Protease Inhibitors
  • Coronavirus 3C Proteases

Supplementary concepts

  • SARS-CoV-2 variants